ClinicalTrials.Veeva

Menu

The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS

B

Brain Inflammation Collaborative

Status

Completed

Conditions

Pediatric Acute-Onset Neuropsychiatric Syndrome
PANS
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
PANDAS
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections

Study type

Observational

Funder types

Other

Identifiers

NCT06818656
BIC-2025-01

Details and patient eligibility

About

The Economic Impact Study of IVIG treatment for PANS is a part of the Unhide™ Project, which is a research initiative developed by the Brain Inflammation Collaborative. Specifically, the Unhide™ project is a collection of investigations with the overall goal of better understanding the problems with thinking and mood that can sometimes be symptoms of conditions like autoimmune disease, infection-associated chronic conditions like Long COVID, ME/CFS, PANDAS, PANS, and other illnesses. Your contribution to this research will allow us to better describe these symptoms and understand what causes them, how they develop, and how they can best be treated and prevented.

This study seeks to assess how PANDAS/PANS affects the financial well-being of families who pursue IVIG treatment, as well as the overall health and quality of life of children with the condition. By gathering data through this survey, we aim to gain important insights into the economic consequences of treating - or not treating - PANS with IVIG, including how it impacts parents' ability to work and children's ability to attend school.

Key Eligibility Criteria

  • Aged 2-89, U.S. resident, fluent in English, and have access to computer and/or smartphone
  • Suspected or confirmed diagnosis of PANS/PANDAS
  • Have received IVIG OR have sought and/or been prescribed IVIG but have not received it

Enrollment

65 patients

Sex

All

Ages

2 to 89 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Individuals who who have, or have had, a healthcare provider-diagnosed or suspected diagnosis of PANDAS and/or PANS
  • Have received IVIG OR have sought and/or been prescribed IVIG but have not received it
  • Fluent in English, sufficient to communicate status via the ePRO instrument as required by the protocol
  • Is a U.S. resident
  • Access to a computer and/or smartphone and the internet, and possessing the ability to operate those devices without assistance from another person (except that children can be assisted by their parents/guardians).

Exclusion criteria

  • Ward of state
  • Failure to meet inclusion criteria

Trial contacts and locations

1

Loading...

Central trial contact

Megan L. Fitzgerald, PhD; Christy Jagfeld, CPA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems